文章摘要
王晓琼,童骁,汤恒,刘萍萍,张伟,杨荣阁.湖北省抗病毒治疗和未治疗的HIV-1感染者耐药基因变异研究[J].中华流行病学杂志,2007,28(11):1112-1115
湖北省抗病毒治疗和未治疗的HIV-1感染者耐药基因变异研究
Study on gnotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV·1 infectious patients in Hubei province
投稿时间:2007-06-28  
DOI:
中文关键词: 艾滋病病毒;耐药变异;高效抗逆转录病毒治疗
英文关键词: HIV;Drug resistance mutations;Highly active antiretroviral therapy
基金项目:国家“973计划”资助项目(2005cB522903);国家“863计划”资助项目(2005AA219070)
作者单位E-mail
王晓琼 中国科学院武汉病毒研究所艾滋病实验室病毒学国家重点实验室, 武汉, 430071  
童骁 中国科学院武汉病毒研究所艾滋病实验室病毒学国家重点实验室, 武汉, 430071  
汤恒 湖北省疾病预防控制中心性病艾滋病防治所  
刘萍萍 中国科学院武汉病毒研究所艾滋病实验室病毒学国家重点实验室, 武汉, 430071  
张伟 中国科学院武汉病毒研究所艾滋病实验室病毒学国家重点实验室, 武汉, 430071  
杨荣阁 中国科学院武汉病毒研究所艾滋病实验室病毒学国家重点实验室, 武汉, 430071 ryang@wh.iov.cn 
摘要点击次数: 762
全文下载次数: 394
中文摘要:
      目的研究湖北省流行的HIV一1毒株在经过高效抗逆转录病毒治疗(HAART)及未治疗人群中耐药基因变异情况。方法采集HIV一1感染者抗凝外周血,提取前病毒DNA,用巢式PcR方法扩增HIv-1声o£基因约2 kb的核酸序列,进行序列测定并通过斯坦福耐药基因数据库进行耐药基因型分析。结果抗病毒治疗组19例,未治疗组25例。在所有的HIV一1感染者样本序列中,发现针对蛋白酶抑制剂(PIs)的耐药突变:D30N(2.27%),D30G(2.27%),M46I(4.55%),M46N(2.27%),147v(4.55%).184v(4.55%),184L(2.27%),N88S(2.27%),L90S(2.27%),以及针对PIs的次要耐药基因突变;A71T(29.55%)。在治疗组中出现针对逆转录酶抑制剂(NRTIs及NNRTIs)的主要耐药基因突变的样本5例,突变主要有M41L(5.26%),A62V(5.26%),D67N(5.26%),L210w(5.26%),T215Y(15.79%);K103E(5.26%),K103N(10.53%),Y181C(5.26%),G190A(5.26%),K238N(5.26%)。在未治疗组中出现针对逆转录酶抑制剂(NRTIs及NNRTIs)的主要耐药基因突变的样本5例,突变主要有M184V(4%),K65N(4%),Y115M(4%),F116L(4%),M184I(4%);V179D(4%),G190R(4%)。在逆转录酶(RT)基因中耐药意义不明的突变F214L,与药物的使用有统计学上的相关性(P=O.03)。结论湖北省HIv一1感染者RT基因的耐药突变,在治疗和未治疗人群样本中差异有统计学意义,说明药物治疗已经对HIV耐药基因突变的产生有了一定影响。同时,耐药意义尚未明确的突变位点F214L也可能与治疗或是某些药物的使用有一定的相关性。
英文摘要:
      objective To study the drug resistance status on HIV一1 patients who had been treatedwith highly active antiretroviral therapy(HAART)and those treatment-naive ones in Hubei province.methods Nested polymerase chain reaction(PCR)was used to amplifv 2 kb DNA fragment in HIV声oZgene from peripheral blood of the HIV infected patients and the PCR products were sequenced. Thesequences were compared to the StanfOrd HIV drug resistance database. results Nineteen patients weretreated with regimens composed of two Nucleoside Reverse Transc“ptase Inhibitors(NRTIs)and one Non-NucleOside Reverse Transcriptase Inhibjtors(NNRTI),with 25 patients as treatment-naive.Some protease(PR)drug_resistant mutations were found in these samples,such as D30N(2.27%),D30G(2.27%),M46I(4.55%),M46N(2.27%),147V(4.55%),184V(4.55%),184L(2.27%),N88S(2.27%)andL90S(2.27%)that all belonged to major drug+resistant but A71T(29.55%)belonged to minor resistancemutations Five treated patients were detected having mutations associated RT drug resistance: M41L(5.26%),A62V(5.26%),D67N(5.26%),L210w(5.26%),T215Y(15.79%);K103E(5.26%),K103N(10.53%),Y181C(5.26%),G190A(5.26%),K238N(5.26%),while five treatment-naivepatients were detected to have had mutations associated RT drug resistance M184V(4%),K65N(4%),Y115M(4%),F116L(4%),M184I(4%),V179D(4%),G190R(4%).Some additional mutations were detected in RT whose mle inv01ve in drug resistance still remained unknown. F214L was positivelyassociated with HAART treatment(PCR0.03).conclusion Significant differences were found betweendrug resistance mutations to RTIs in treated and treat-naTve patients in Hubei province,indicating that drugshad affected the occurrence of drug resistance mutations. At the same time,novel RT mutations F2 1 4Lmight be associated with HAART or some other drugs.
查看全文   Html全文     查看/发表评论  下载PDF阅读器
关闭